Slingshot members are tracking this event:

Results of Factor Xa inhibitor rivaroxaban (Xarelto) from studies COMMANDER HF and MARINER studies presented at ESC Congress 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
“Sudden worsening of the symptoms of heart failure is serious and often requires hospitalization to manage worsening breathlessness and swelling of the legs,” said Professor John Cleland, Professor of Cardiology at Imperial College London, UK. “While the COMMANDER HF study demonstrated that rivaroxaban offers no additional benefit on top of standard of care in this group of patients
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 27, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Xarelto, Rivaroxaban, Commander Hf, Mariner